DelveInsight's 'Anal Cancer - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Anal Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Anal Cancer epidemiology report gives a thorough understanding of the Anal Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Anal Cancer in the US, Europe, and Japan. The report covers the detailed information of the Anal Cancer epidemiology scenario in seven major countries (US, EU5, and Japan).
The Anal Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Anal Cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Anal Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Anal Cancer epidemiology covered in the report provides historical as well as forecasted Anal Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Anal Cancer report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Anal Cancer
3. Anal Cancer: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Anal Cancer Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Anal Cancer Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Anal Cancer Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Anal Cancer Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Anal Cancer Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Anal Cancer Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Anal Cancer Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Anal Cancer Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Anal Cancer Treatment and Management
6.2. Anal Cancer Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Anal Cancer Epidemiology in 7MM (2017-2030)
Table 2 Anal Cancer Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Anal Cancer Epidemiology in the United States (2017-2030)
Table 4 Anal Cancer Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Anal Cancer Epidemiology in Germany (2017-2030)
Table 6 Anal Cancer Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Anal Cancer Epidemiology in France (2017-2030)
Table 8 Anal Cancer Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Anal Cancer Epidemiology in Italy (2017-2030)
Table 10 Anal Cancer Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Anal Cancer Epidemiology in Spain (2017-2030)
Table 12 Anal Cancer Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Anal Cancer Epidemiology in the United Kingdom (2017-2030)
Table 14 Anal Cancer Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Anal Cancer Epidemiology in Japan (2017-2030)
Table 16 Anal Cancer Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Anal Cancer Epidemiology in 7MM (2017-2030)
Figure 2 Anal Cancer Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Anal Cancer Epidemiology in the United States (2017-2030)
Figure 4 Anal Cancer Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Anal Cancer Epidemiology in Germany (2017-2030)
Figure 6 Anal Cancer Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Anal Cancer Epidemiology in France (2017-2030)
Figure 8 Anal Cancer Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Anal Cancer Epidemiology in Italy (2017-2030)
Figure 10 Anal Cancer Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Anal Cancer Epidemiology in Spain (2017-2030)
Figure 12 Anal Cancer Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Anal Cancer Epidemiology in the United Kingdom (2017-2030)
Figure 14 Anal Cancer Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Anal Cancer Epidemiology in Japan (2017-2030)
Figure 16 Anal Cancer Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report
